MetaCap

Gelteq (GELS) vs Kiora Pharmaceuticals (KPRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kiora Pharmaceuticals is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GELS-51.78%KPRX-71.53%
+5%-35%-75%
Oct 7, 20261 yearNov 20, 2026
GELS-48.18%KPRX-71.65%
+4%-36%-75%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GELS versus KPRX key metrics
MetricGELSKPRX
Share price$0.2701$0.7202
Market cap$3.11M$3.19M
1-day change-3.74%-12.28%
YTD return—-63.44%
1-year return—-61.49%
5-year return—-99.87%
EPS (TTM)$-0.44$-2.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-6.65M$-10.84M
52-week high$2.01$2.91
52-week low$0.255$0.72
Distance from 52-week high-86.56%-75.25%
Analyst consensus—none
Avg. price target upside—+1566.20%
Average volume2.85M35.23K
Shares outstanding11.51M4.42M
Employees713
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Gelteq

GELS stock →

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Kiora Pharmaceuticals

KPRX stock →

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

GELS vs KPRX FAQ

Which is bigger, Gelteq or Kiora Pharmaceuticals?

Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $3.19M compared with $3.11M for Gelteq (GELS).

Are Gelteq and Kiora Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons